Elysium Therapeutics, Inc. — Form D
Elysium Therapeutics, Inc. of AKRON, OH, a company, filed a Form D exempt-offering notice with the SEC on 2019-03-25. The offering totals $1.5M, of which $215K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-03-25
- Form: D
- Accession: 0001726100-19-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.5M
- Amount sold: $215K
- Remaining: $1.3M
- Minimum investment: $1
- Investors: 4
- Date of first sale: 2019-03-08
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-335538
Issuer
- Name: Elysium Therapeutics, Inc.
- CIK: 0001726100
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 1201 East Market St., Suite 604, AKRON, OH, 44305
- Phone: (925) 399-7246
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Thomas E Jenkins | Director | Danville, CA |
| Kathy E LaPorte | Director | Danville, CA |
| Bob E Rappaport | Director | Danville, CA |
| Thomas E Jenkins | Executive Officer | Danville, CA |
| Alex Gregory Sturmer | Director | Akron, OH |
| Alex Gregory Sturmer | Executive Officer | Akron, OH |
| Thomas Gregory Jenkins | Director | Akron, OH |
| James Gregory Hackworth | Director | Akron, OH |
| Bob Gregory Rappaport | Director | Akron, OH |
| Kathy Gregory LaPorte | Director | Akron, OH |
| Carey Gregory Ng | Director | Akron, OH |
Other filings by this issuer (4)
More